Auxogyn, Inc. Appoints Women's Health Leader, Kathryn A. Tunstall, to Board of Directors
MENLO PARK, CA--(Marketwire - February 28, 2013) -
| Highlighted Links |
Auxogyn |
"Kathryn is a valuable addition to our board with her extensive experience in the field of women's reproductive health and leadership in growing early stage companies to successful enterprises. Kathryn was the first CEO of Conceptus and under her leadership, the company rapidly grew to be a worldwide leader in bringing innovative solutions to the field of women's reproductive health," said Lissa Goldenstein, president and chief executive officer of Auxogyn. "Her experience will be instrumental in this next stage for Auxogyn, as we continue to expand the commercialization of our flagship product, the Eeva™ Test, which is currently available throughout the UK and Ireland."
Ms. Tunstall has served as chairman of the Board of Directors of Conceptus, Inc., since January 2000 and as a member of the company's Board of Directors since her appointment as CEO in July 1993. Prior to joining Conceptus, she was employed by Edwards Less Invasive Surgery Division of Baxter International, where she held a number of positions including president. Earlier in her career, she held various positions in finance, operations and marketing at American Hospital Supply Corporation. Ms. Tunstall also served as a director and compensation committee chair of Caliper LifeSciences, a publicly-traded biotechnology company, until its acquisition by Perkin Elmer, Inc. in November, 2011. She holds a B.A. in economics from the University of California and has completed graduate-level studies in business and healthcare administration.
"With one in six couples experiencing infertility, there is a tremendous need for technology to improve outcomes in order to help couples achieve their dream of having a healthy child. I'm pleased to be joining the Board of Directors at Auxogyn," said Kathryn Tunstall. "The Eeva Test brings a technological breakthrough to in vitro fertilization (IVF), offering objective information to clinical teams to predict which embryos are the most viable and ultimately, to help patients increase their odds for success."
About the Eeva™ Test
Auxogyn's non-invasive Early Embryo Viability Assessment (Eeva) Test is designed to improve IVF outcomes by providing clinicians and patients with objective information that will enable them to more confidently select the best embryo(s) for transfer. Eeva provides quantitative and objective information on the early stages of the embryo's development and predicts the viability of each embryo. Eeva's proprietary software automatically analyzes embryo development against scientifically and clinically validated cell-division parameters. With Eeva, IVF clinics may be able to optimize the treatment path for their patients undergoing IVF procedures. The Eeva Test is CE Mark approved and is available in clinics throughout the United Kingdom and Ireland. In the United States, the Eeva Test is pending 510K clearance and is limited to investigational use only. For more information regarding Eeva, please visit eevaivf.com or follow on Twitter @ EevaIVF.
About Auxogyn
Auxogyn is revolutionizing the field of reproductive medicine by translating scientific discoveries in early embryo development into clinical tools. The Company's flagship product, the Eeva™ Test, delivers consistent, objective and quantitative information regarding embryo viability that reproductive endocrinologists and infertility patients can use to make important treatment decisions. Auxogyn is privately held and funded by Kleiner Perkins Caufield & Byers, Merck Serono Ventures, SR One and TPG Biotech. For more information regarding Auxogyn, please visit www.auxogyn.com or follow on Twitter @Auxogyn.